MLND - Millendo Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.80
+0.48 (+3.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.32
Open15.10
Bid7.05 x 800
Ask16.66 x 800
Day's Range14.81 - 16.17
52 Week Range6.77 - 17.34
Volume13,013
Avg. Volume27,135
Market Cap211.056M
Beta (3Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-17.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • Will OvaScience Continue to Surge Higher?
    Zacks16 days ago

    Will OvaScience Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in OvaScience.

  • Business Wire17 days ago

    Millendo Therapeutics, Inc. to Present at the 18th Annual Needham Healthcare Conference

    Millendo Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference in New York City on Tuesday, April 9, 2019 at 12:00 p.m.

  • Business Wire21 days ago

    Millendo Reports Full Year 2018 Operating and Financial Results

    --Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome , in 1Q19--

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • Business Wirelast month

    Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome

    Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that it has initiated its pivotal Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome (PWS). The study, called ZEPHYR, will evaluate the safety and efficacy of livoletide on food-related behaviors in PWS patients. The primary endpoint is an assessment of livoletide’s impact on hyperphagia, the excessive hunger which is a hallmark symptom of the disease.

  • Business Wirelast month

    Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia

    Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its clinical candidates, livoletide (AZP-531) and nevanimibe (ATR-101), will be featured in three poster presentations at ENDO 2019, taking place March 23-26, 2019 in New Orleans, La. Livoletide, a potential first-in-class treatment for Prader-Willi syndrome (PWS), will be featured in two poster sessions. The company will provide an overview of the study design for the pivotal Phase 2b/3 ZEPHYR clinical trial to evaluate the safety and efficacy of livoletide for hyperphagia and related food-related behaviors in PWS patients in one poster session.

  • Business Wire2 months ago

    Millendo Therapeutics, Inc. to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference

    Millendo Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

  • Business Wire2 months ago

    Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST. Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient.

  • Business Wire3 months ago

    Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Millendo Therapeutics, Inc. (“Millendo” or the “Company”) (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that on January 28, 2019, the Compensation Committee of the Board of Directors approved, effective as of January 31, 2019, the grant of inducement stock options to purchase a total of 34,100 shares of the Company’s common stock to three newly-appointed employees of the Company. The option awards have an exercise price of $10.48 per share, the closing price per share of the Company’s common stock on January 31, 2019.